| Bioactivity | FR-146687 (FK 687) is a selective and orally active 5α-reductase inhibitor with IC50s of 1.7 nM and 4.6 nM for rat and human 5α-reductases, respectively. FR-146687 shows no inhibitory effects on other steroid oxidoreductases[1]. |
| Target | IC50: 1.7 nM (Rat 5α-reductase) and 4.6 nM (Human 5α-reductase) |
| In Vivo | FR-146687 (0.032-3.2 mg/kg；口服；2、7、14 或 21 天) 剂量依赖性地在剂量高于 0.1 mg/kg 时减少腹侧前列腺和精囊重量[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: |
| CAS | 146939-64-2 |
| Formula | C33H37NO4 |
| Molar Mass | 511.65 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. O Nakayama, et al. FR146687, a novel steroid 5 alpha-reductase inhibitor: in vitro and in vivo effects on prostates. Prostate. 1997 Jun 1;31(4):241-9. |